Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients’ expectations and preferences from the prospective, non-interventional SATIS-Fab study

Abstract Background Fabry disease (FD) is a progressive X-linked lysosomal disorder caused by GLA variants resulting in deficient α-galactosidase A enzyme activity, glycolipid accumulation, and multisystemic dysfunction. Approved treatments include intravenous enzyme replacement therapy (ERT) or the...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Olivier Lidove, Agathe Masseau, Grégory Pugnet, Didier Lacombe, Bertrand Dussol, Soumeya Bekri, Albert Hagège, Caroline Martinez, Yann Fardini, Alain Fouilhoux, Esther Noël
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-04-01
Serija:	Orphanet Journal of Rare Diseases
Teme:	Fabry disease Migalastat Enzyme replacement therapy Treatment expectations Treatment satisfaction Patient Benefit Index
Online dostop:	https://doi.org/10.1186/s13023-026-04285-7
Oznake:	Označite Brez oznak, prvi označite!